UnknownNot Applicable

Almonertinib Plus Metronomic Oral Vinorelbine

40 participantsStarted 2022-12-20

Plain-language summary

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy for these patients.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Non-small cell lung cancer diagnosed by histopathology or cytology; * Previous molecular pathology was EGFR sensitive mutation; * Stage IV; * ECOG score 0-2; * Prior to receiving the third generation of EGFR-TKI targeted therapy, and TKI targeted therapy showed limited progress; * According to RECIST1.1 standards, there are measurable or evaluable lesions * The patient has fully understood this study and voluntarily signed a written informed consent form; * The estimated survival time is more than 3 months. Exclusion Criteria: * Histological or cytological confirmation of small cell lung cancer or squamous cell carcinoma at the first diagnosis; * The progression of the third generation EGFR-TKI suggests histological transformation.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

PFS

Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Trial details

NCT IDNCT05663177

SponsorFujian Cancer Hospital

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2023-12-20

View on ClinicalTrials.gov More EGFR trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.